CALGB 150905 (Alliance): Rituximab broadens the anti-lymphoma response by activating unlicensed NK cells
- Citation:
- Cancer Immunol Res vol 2 (9) 878-889
- Year:
- 2014
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 4
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U10 CA032291, CA33601, CA77597, U10 CA077658, CA77406, AI068129, CA32291, CA29165, U10 CA045564, CA41287, U10 CA045808, CA03927, U10 CA031946, CA77651, NIH AI068129, U10 CA033601, U10 CA045389, CA59518, CA60138, U10 CA180821, CA26806, CA45389, U10 CA077597, CA45808, U10 CA059518, U10 CA114558, U10 CA077440, CA16450, CA77440, U10 CA041287, CA45564, U10 CA047559, U10 CA077651, CA04326, CA74811, R01 AI068129, CA47559, CA114558-02, CA47642, U10 CA074811, CA77658, U10 CA180867, U10 CA047642, CA31946, U10 CA003927, CA07968
- Corr. Author:
- Authors:
- Juan Du Sandra Lopez-Verges Brandelyn N. Pitcher Jeffrey Johnson Sin-Ho Jung Lili Zhou Katharine Hsu Myron S. Czuczman Bruce Cheson Lawrence Kaplan Lewis L. Lanier Jeffrey M. Venstrom
- Networks:
- Study
- CALGB-150905
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-50402, CALGB-50701
- Phases:
- N/A, 2
- Keywords:
- natural killer, KIR, ADCC, lymphoma, rituximab